The European Commission sanctioned pharmaceutical firms Johnson & Johnson and Novartis with fines totaling $21.95 million for their payments to block a generic version of a drug in a pay-for-delay deal, a day after Commissioner Joaquin Almunia spoke on the anticompetitive effects of such agreements.
In a statement released Tuesday, the Commission said the companies were found to have blocked the sale of a generic, cheaper version of a painkiller in the Netherlands beginning in July 2005, leading to higher costs for consumers for more than a year.
J&J and Novartis’s Dutch companies were each fined.
In the statement, Almunia said companies should “think twice” before entering into such agreements, which have been the focus of a widespread crackdown for various regulators around the globe.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Court Order Temporarily Halts U.S. Consumer Financial Protection Bureau Layoffs
Feb 16, 2025 by
CPI
Nokia Poised to Gain EU Approval for $2.3 Billion Infinera Acquisition
Feb 16, 2025 by
CPI
Turkey Fines Frito-Lay in Antitrust Crackdown
Feb 16, 2025 by
CPI
Advances Bill to Strengthen Antitrust Enforcement Through AI
Feb 16, 2025 by
CPI
Intel Faces Potential Breakup as Broadcom and TSMC Explore Deals
Feb 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon